Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted...
GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.
INDIANAPOLIS , April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call...
In ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 events
BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm
1 Profitable Stock to Own for Decades and 2 That Underwhelm
/Eli%20Lilly%20%26%20Co_%20by%20Tada%20Images%20via%20Shutterstock.jpg)
Eli Lilly is approaching its first-quarter earnings release this month, and Wall Street is forecasting a triple-digit percentage rise in earnings.
Foundayo is now available via LillyDirect ® and telehealth providers and is shipping to retail pharmacies nationwide
Nuclear, pharma, and travel giants just made significant buyback announcements. However, not all of these are as confidence-inspiring as they may seem.